The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial
Abstract
Background Bifidobacterium bifidum MIMBb75 is one of a few probiotic strains that have been shown to be effective in the treatment of irritable bowel syndrome (IBS) and its symptoms. Non-viable strains might have advantages over viable bacteria for product stability and standardisation, as well as for tolerability because safety concerns have been raised for specific patient groups who are susceptible to infection. We aimed to assess the efficacy of non-viable, heat-inactivated (HI) B bifidum MIMBb75 (SYN-HI-001) in the treatment of IBS and its symptoms.Methods We did a double-blind, placebo-controlled trial in which patients with IBS were recruited from 20 study sites in Germany and randomly assigned to receive either two placebo capsules or two capsules with a combined total of 1 × 10 9 non-viable B bifidum HI-MIMBb75 cells to be taken orally once a day for 8 weeks. Eligible patients were diagnosed with IBS according to Rome III criteria and had abdominal pain (≥4 on an 11-point numerical rating scale) on at least 2 days during a 2-week run-in phase. Patients with chronic inflammatory bowel diseases, systemic diseases, cancer, autoimmune diseases, with an intake of antipsychotic medications 3 months before study start, or with an intake of systemic corticosteroids within 1 month before study start were excluded. Randomisation was in a 1:1 ratio according to a computer-generated blocked list. Patients, investigators, clinical monitors, project managers, and statisticians were masked to the randomisation. The primary composite endpoint was the combination of at least 30% improvement of abdominal pain and adequate relief of overall IBS symptoms being fulfilled in at least 4 of 8 weeks during treatment. Analysis of the primary endpoint included all randomly assigned patients receiving at least one dose of study medication and who had no severe protocol violation. Safety analysis included all patients who had taken at least one dose of the study medication and was based on frequency and severity of adverse events, laboratory evaluation, and global assessment of tolerability. This trial is registered with the ISRCTN registry, ISRCTN14066467, and is completed: the results shown here represent the final analysis.Findings Patients were screened between April 15, 2016, and Feb 3, 2017, and 443 patients were allocated to the placebo group (n=222) or the B bifidum HI-MIMBb75 group (n=221). The composite primary endpoint was reached by 74 (34%) of 221 patients in the B bifidum HI-MIMBb75 group compared with 43 (19%) of 222 in the placebo group (risk ratio 1·7, 95% CI 1·3-2·4; p=0·0007). No serious adverse events occurred in the B bifidum HI-MIMBb75 group; seven adverse events suspected to be related to the study product were reported in the B bifidum HI-MIMBb75 group as were eight in the placebo group. No deaths were reported in this study. The most common reported adverse event with a suspected relationship to the study product was abdominal pain, which was reported in two (<1%) patients in the B bifidum HI-MIMBb75 group and one (<1%) in the placebo group. Tolerability was rated as very good or good by 200 (91%) patients in the B bifidum HI-MIMBb75 group compared with 191 (86%) in the placebo group.Interpretation This study shows that B bifidum HI-MIMBb75 substantially alleviates IBS and its symptoms in a real-life setting. These results indicate that specific beneficial bacterial effects are mediated independently of cell viability.Funding Synformulas.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We updated a prior meta-analysis of 37 RCTs, 158 incorporating data from 8 new trials [166][167][168][169][170][171][172][173] and randomising 6352 patients.”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [167]
In the citing paper
“In addition, inactive probiotics and heat-inactivated probiotics have been shown to be effective in improving constipation [26,57], suggesting that they may have advantages over some live probiotics in terms of stability and safety for patients with compromised enterobacterial defenses of treatment.”
From Chronic constipation and gut microbiota: current research insights and therapeutic implications (2024) · cites this paper as [57]
In the citing paper
“In addition, inactive probiotics and heat-inactivated probiotics have been shown to be effective in improving constipation [26,57], suggesting that they may have advantages over some live probiotics in terms of stability and safety for patients with compromised enterobacterial defenses of treatment.”
From Chronic constipation and gut microbiota: current research insights and therapeutic implications (2024) · cites this paper as [57]
Citations
Cites
Besselink, M. G., van Santvoort, H. C., Buskens, E., Boermeester, M. A., van Goor, H., Timmerman, H. M., Nieuwenhuijs, V. B., Bollen, T. L., van Ramshorst, B., Witteman, B. J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60207-x · Cited by 1,367
Isolauri, E., Juntunen, M., Rautanen, T., Sillanaukee, P., & Koivula, T. (1991) · PubMed · Cited by 684
Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619
Piche, T., Barbara, G., Aubert, P., Bruley des Varannes, S., Dainese, R., Nano, J. L., Cremon, C., Stanghellini, V, De Giorgio, R., Galmiche, J. P., et al. (2009) · Gut · doi:10.1136/gut.2007.140806 · Cited by 540
The probiotic paradox: live and dead cells are biological response modifiers
Adams, C. A. (2010) · Nutrition Research Reviews · doi:10.1017/s0954422410000090 · Cited by 521
The Health Effects of Cultured Milk Products with Viable and Non-viable Bacteria
Ouwehand, A. C., & Salminen, S. J. (1998) · International Dairy Journal · doi:10.1016/s0958-6946(98)00114-9 · Cited by 434
Invasive Saccharomyces Infection: A Comprehensive Review
Enache-Angoulvant, A., & Hennequin, C. (2005) · Clinical Infectious Diseases · doi:10.1086/497832 · Cited by 369
Review article: epidemiology and quality of life in functional gastrointestinal disorders
Chang, L. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02183.x · Cited by 351
Resta–Lenert, S., & Barrett, K. E. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.015 · Cited by 310
Marshall, J. K., Thabane, M., Garg, A. X., Clark, W., Meddings, J., Collins, S. M., & for the WEL Investigators (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02284.x · Cited by 292
Cited by
Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00440-6 · Cited by 2,488
Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0344-2 · Cited by 2,196
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Vinderola, G., Sanders, M. E., & Salminen, S. (2022) · Foods · doi:10.3390/foods11081077 · Cited by 371
“The inanimate culture was able to substantially alleviate symptoms in a real-life setting [23].”
BackgroundGut liver brain axis in diseases: the implications for therapeutic interventions
Yan, M., Man, S., Sun, B., Ma, L., Guo, L., Huang, L., & Gao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01673-4 · Cited by 287
Metadata
- Authors
- Andresen, V., Gschossmann, J., & Layer, P.
- Affiliations
- Universität Hamburg (DE)
- Corresponding author
- Layer, Peter
- ORCID
- Andresen, Viola
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 5
- Issue
- 7
- Pages
- 658-666
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W3016114396
- Cited by
- 206
- References
- 34
- Citations by year
- 2026: 26 · 2025: 35 · 2024: 43 · 2023: 37 · 2022: 33 · 2021: 18 · 2020: 14
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet. Gastroenterology & hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, heat-inactivated probiotics, abdominal pain, probiotic safety, tolerability, Rome III criteria, dysbiosis, gut microbiota, dyspepsia, irritable bowel syndrome with constipation
- MeSH terms
- Bifidobacterium bifidum, Adult, Double-Blind Method, Female, Germany, Humans, Intestines, Male, Middle Aged, Pain Measurement, Placebos, Safety, Abdominal Pain, Case-Control Studies, Treatment Outcome, Probiotics, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. https://app.cochat.ai/papers/10.1016/s2468-1253(20)30056-x
- The paper
- Andresen, V., Gschossmann, J., & Layer, P. (2020). Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(20)30056-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.